Ernexa Therapeutics (ERNA) Equity Average (2016 - 2025)
Historic Equity Average for Ernexa Therapeutics (ERNA) over the last 15 years, with Q3 2025 value amounting to $4.0 million.
- Ernexa Therapeutics' Equity Average rose 11486.3% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 11486.3%. This contributed to the annual value of $2.0 million for FY2024, which is 7256.62% down from last year.
- As of Q3 2025, Ernexa Therapeutics' Equity Average stood at $4.0 million, which was up 11486.3% from -$753000.0 recorded in Q2 2025.
- In the past 5 years, Ernexa Therapeutics' Equity Average ranged from a high of $42.6 million in Q3 2021 and a low of -$27.0 million during Q3 2024
- Its 5-year average for Equity Average is $6.5 million, with a median of $4.8 million in 2023.
- Per our database at Business Quant, Ernexa Therapeutics' Equity Average skyrocketed by 29554.35% in 2021 and then crashed by 85396.03% in 2024.
- Ernexa Therapeutics' Equity Average (Quarter) stood at $42.6 million in 2021, then tumbled by 75.43% to $10.5 million in 2022, then plummeted by 72.3% to $2.9 million in 2023, then plummeted by 853.96% to -$21.8 million in 2024, then skyrocketed by 118.34% to $4.0 million in 2025.
- Its last three reported values are $4.0 million in Q3 2025, -$753000.0 for Q2 2025, and -$2.1 million during Q1 2025.